PureIR
中文
Menu
About PureIR Game On

Listed Companies

Medical Devices

Consumer Healthcare

Healthcare Technology

Editorial Method

HKEX 01609 · Unpaid pilot profile

Star Sports Medicine

Beijing Star Sports Medicine Co., Ltd.

Star Sports Medicine is a sports-medicine medical-device company whose biomaterials, imaging and power, smart healthcare and regenerative-medicine tissue-engineering platforms support implants, surgical equipment and related consumables. In the first half of 2026, revenue was RMB163.427 million, gross margin was 74.2%, profit for the period was RMB27.402 million and adjusted profit was RMB48.897 million; its products had entered more than 3,000 hospitals in China.

Disclosure through2026-06-30 Page reviewed2026-08-30 Listed onHong Kong Stock Exchange
Page two · play it → Official investor-relations website Operations · 2026 interim results · PDF page 10

This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement.

Let movement become the body's language again 00

Press and drag to let the repair pathway stabilise the joint

  1. 01Biomaterials
  2. 02Imaging and power
  3. 03Smart healthcare
  4. 04Regenerative medicine

An editorial metaphor for the disclosed four technology platforms and sports-medicine portfolio; it does not represent an individual treatment, repair or rehabilitation outcome.

RMB163.4m Interim revenue Six months ended 30 June 2026 RMB48.9m Adjusted profit for the period Six months ended 30 June 2026 RMB40.7m Overseas revenue Six months ended 30 June 2026 Continue through the disclosure

Latest formal disclosure

2026 interim results

Formal interim results · unaudited Announcement published 17 August 2026

Interim revenue

RMB163.4m Up 21.6%; gross profit increased 21.8% to RMB121.296 million. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Interim reported profit

RMB27.4m Down 26.1%; company-reported non-IFRS adjusted profit for the period was RMB48.897 million, up 24.3%. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Overseas revenue

RMB40.7m Up 70.6% and representing 24.9% of revenue; the company disclosed more than 200 regulatory approvals and registrations across over 60 countries and regions. Six months ended 30 June 2026 · RMB million HKEX · PDF page 10

The figures below are from the formal interim-results announcement for the six months ended 30 June 2026 and are unaudited. Historical annual charts use the audited FY2023–FY2025 track record in the prospectus, with interim figures shown separately.

Disclosure highlights

Latest disclosed facts

Cover of Star Sports Medicine's 2026 prospectus
Star Sports Medicine 2026 prospectus · HKEX; latest data come from the 2026 interim results
01

Interim revenue

RMB163.4m

Up 21.6%; gross profit increased 21.8% to RMB121.296 million.

Six months ended 30 June 2026 · RMB million HKEX · PDF page 1
02

Adjusted profit for the period

RMB48.9m

Up 24.3%; reported profit for the period was RMB27.402 million, with the difference primarily including listing expenses.

Six months ended 30 June 2026 · RMB million (non-IFRS) HKEX · PDF page 1
03

Overseas revenue

RMB40.7m

Up 70.6% and representing 24.9% of revenue; the company held more than 200 regulatory approvals and registrations across over 60 countries and regions.

Six months ended 30 June 2026 · RMB million HKEX · PDF page 10

Disclosure reading

How to read the disclosure

PureIR disclosure synthesis

Four technology platforms connect the product portfolio

The biomaterials, imaging and power, smart healthcare and regenerative-medicine tissue-engineering platforms underpin implants, active surgical devices, sports-medicine surgical robots, AI exercise prescriptions and regenerative-medicine devices.

HKEX · PDF page 11

PureIR disclosure synthesis

Hospital coverage supports domestic commercialisation

At 30 June 2026, the company's products had entered more than 3,000 hospitals in China, including over 1,000 tertiary hospitals. This indicates distribution and clinical coverage, not hospital purchasing volume or end-use volume.

HKEX · PDF page 10

PureIR disclosure synthesis

Overseas growth and registrations advance together

Overseas revenue grew 70.6% in the first half of 2026 and its revenue share rose to 24.9%; the company also disclosed more than 200 regulatory approvals and registrations across over 60 countries and regions.

HKEX · PDF page 10

PureIR disclosure synthesis

Reported and adjusted profit should be read together

Profit for the first half of 2026 was RMB27.402 million, down 26.1%. After adjustments including listing expenses, company-reported non-IFRS profit was RMB48.897 million, up 24.3%.

HKEX · PDF page 17
Simplified 3D illustration of a suture anchor connecting tendon to bone

Explore the principles

Sports medicine, in 3D.

How do anchors, screws and cortical buttons help hold injured tissue? Explore the connections through five interactive illustrations.

Enter the interactive lab Simplified educational models · not medical advice

Business model

Business revenue

Implants revenue

RMB 125.436 million 2026H1 PDF page 7

Surgical equipment and related consumables revenue

RMB 37.815 million 2026H1 PDF page 7

Annual series

Revenue mix by business (RMB)

Revenue mix by business (RMB), unit: RMB million 435 326 217 109 0 FY2023FY2024FY2025 Implants revenue FY2023: 186.5 RMB million Surgical equipment and related consumables revenue FY2023: 51.9 RMB million Implants revenue FY2024: 250.0 RMB million Surgical equipment and related consumables revenue FY2024: 77.0 RMB million Implants revenue FY2025: 310.4 RMB million Surgical equipment and related consumables revenue FY2025: 92.0 RMB million
Period: complete fiscal years; business revenue follows company definitions; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 11
View exact values and source pages
MetricPeriodValueSource
Implants revenueFY2023RMB 186.516 millionPDF page 11
Surgical equipment and related consumables revenueFY2023RMB 51.919 millionPDF page 11
Implants revenueFY2024RMB 249.987 millionPDF page 11
Surgical equipment and related consumables revenueFY2024RMB 76.986 millionPDF page 11
Implants revenueFY2025RMB 310.375 millionPDF page 11
Surgical equipment and related consumables revenueFY2025RMB 92.02 millionPDF page 11
Implants revenue2026H1RMB 125.436 millionPDF page 7
Surgical equipment and related consumables revenue2026H1RMB 37.815 millionPDF page 7

Structured disclosure

Financial performance

Interim revenue

RMB 163.427 million 2026H1 PDF page 1

Interim gross profit

RMB 121.296 million 2026H1 PDF page 1

Interim profit for the period

RMB 27.402 million 2026H1 PDF page 1

Annual series

Revenue and gross profit (RMB)

Revenue and gross profit (RMB), unit: RMB million 435 326 217 109 0 FY2023FY2024FY2025 Revenue FY2023: 238.5 RMB million Revenue FY2024: 327.1 RMB million Revenue FY2025: 402.8 RMB million Gross profit FY2023: 177.3 RMB million Gross profit FY2024: 227.6 RMB million Gross profit FY2025: 298.6 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 17

Annual series

Net profit (RMB)

Net profit (RMB), unit: RMB million 148 111 74 37 0 FY2023FY2024FY2025 Net profit FY2023: 57.1 RMB million Net profit FY2024: 95.4 RMB million Net profit FY2025: 137.0 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 17
View exact values and source pages
MetricPeriodValueSource
RevenueFY2023RMB 238.542 millionPDF page 17
Gross profitFY2023RMB 177.308 millionPDF page 17
Net profitFY2023RMB 57.112 millionPDF page 17
RevenueFY2024RMB 327.119 millionPDF page 17
Gross profitFY2024RMB 227.595 millionPDF page 17
Net profitFY2024RMB 95.389 millionPDF page 17
RevenueFY2025RMB 402.751 millionPDF page 17
Gross profitFY2025RMB 298.619 millionPDF page 17
Net profitFY2025RMB 136.97 millionPDF page 17
Interim revenue2026H1RMB 163.427 millionPDF page 1
Interim gross profit2026H1RMB 121.296 millionPDF page 1
Interim profit for the period2026H1RMB 27.402 millionPDF page 1
Interim gross margin2026H174.2%PDF page 15

Structured disclosure

Operating metrics

Hospitals reached by products

3,000 hospitals 2026-06-30 PDF page 10

Tertiary hospitals reached

1,000 hospitals 2026-06-30 PDF page 10

Registered patents

190 patents 2026-06-30 PDF page 14

International regulatory approvals and registrations

200 approvals 2026-06-30 PDF page 10
View exact values and source pages
MetricPeriodValueSource
Hospitals reached by products2026-06-303,000 hospitalsThe company disclosed more than 3,000 hospitals; the canonical value records the disclosed floor.PDF page 10
Tertiary hospitals reached2026-06-301,000 hospitalsThe company disclosed more than 1,000 tertiary hospitals; the canonical value records the disclosed floor.PDF page 10
Approved products2026-06-3063 productsPDF page 13
Registered patents2026-06-30190 patentsPDF page 14
R&D staff2026-06-3089 peoplePDF page 13
International regulatory approvals and registrations2026-06-30200 approvalsThe company disclosed more than 200 approvals and registrations; the canonical value records the disclosed floor.PDF page 10

Structured disclosure

Cash flow

Net cash from operating activities

RMB 157.116 million FY2025 PDF page 20

Cash and cash equivalents

RMB 819.64 million 2026-06-30 PDF page 18

Annual series

Net cash from operating activities (RMB)

Net cash from operating activities (RMB), unit: RMB million 170 127 85 42 0 FY2023FY2024FY2025 Net cash from operating activities FY2023: 79.9 RMB million Net cash from operating activities FY2024: 94.5 RMB million Net cash from operating activities FY2025: 157.1 RMB million
Period: complete fiscal years; fiscal year-end follows company disclosure; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 20
View exact values and source pages
MetricPeriodValueSource
Net cash from operating activitiesFY2023RMB 79.856 millionPDF page 20
Net cash from operating activitiesFY2024RMB 94.515 millionPDF page 20
Net cash from operating activitiesFY2025RMB 157.116 millionPDF page 20
Cash and cash equivalents2026-06-30RMB 819.64 millionPDF page 18

Leadership profile

Senior management

Roles and biographies follow formal disclosure. Portraits are used only when published on the company’s official website.

WD

01 / 03

Wenxing Dong

Founder, Chairman, Executive Director, Chief Executive Officer and General Manager

Responsible for the Group's overall strategy, business direction and R&D decisions, with entrepreneurship and management experience in the medical-device industry.

Biography: annual report PDF page 177
1 / 3

Official market reference

Latest quote on HKEX

PureIR does not display or redistribute market-price data.

View 01609 on HKEX ↗

Formal disclosure

Principal risks

Product development and regulatory conversion

Changes in R&D personnel, funding, validation or clinical-trial outcomes may affect new-product timelines, performance, registration and commercialisation.

HKEX · PDF page 40

Product quality, manufacturing and recalls

Adverse product events, manufacturing disruption or defects may lead to regulatory scrutiny, recalls, liability claims and reputational harm.

HKEX · PDF page 42

Volume-based procurement and pricing pressure

Volume-based procurement and pricing pressure from hospitals and distributors may limit cost pass-through and affect selling prices and margins.

HKEX · PDF page 43

Customer concentration

The five largest customers contributed 57.7% of FY2025 revenue and the largest customer 20.8%; changes in major-customer purchasing may affect revenue.

HKEX · PDF page 16

Evidence

Formal sources and public data

Prospectus with audited FY2023–FY2025 track record370 PDF pagesVoluntary announcement — share repurchase plan2 PDF pagesInterim results for the six months ended 30 June 202625 PDF pagesDownload structured JSON →